TYRA logo

TYRA BIOSCIENCES INC

TYRANASDAQ
🏆 #2211 by market capUS Equity
$21.98▲ $0.52 (+2.38%)
After hours · at close
🔔
Track TYRA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.4%
7d▼ 14.0%
14d▼ 13.7%
30d▼ 12.1%
ytd▼ 16.2%
1y▲ 66.0%
🏦Market Cap
$1.31B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
76
Good

Trading Snapshot

Day Range
$21.77 – $22.14
52-Week Range
$12.40 – $40.65
Volume
$2.22B
Avg Volume
$2.53B
Shares Outstanding
59.5M
Next Earnings
Nov 26, 2026

Fundamentals Snapshot

Annual Revenue
$107M
Last Q Revenue
$28M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-2.39
Dividend Yield
—
Dilution (1yr)
+1.2%

Why Investors Own TYRA

  • ✓High-growth profile — revenue up +55.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 68% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TYRA logo

TYRA BIOSCIENCES INC

TYRA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$133M▲ +27.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$95M▲ +35.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
59.6M▲ +1.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$72M▼ −$14M YoY
StockOtter · stockotter.space

About TYRA BIOSCIENCES INC

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$25.61
▲ +16.5% Upside
High Target$30.34
Low Target$21.05
Based on 22 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

TYRA BIOSCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift TYRA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

TYRA BIOSCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.